Page 8 - Stephen Squinto News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Stephen squinto. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Stephen Squinto Today - Breaking & Trending Today

Chemomab Completes Merger with Anchiano Therapeutics

Chemomab Completes Merger with Anchiano Therapeutics
USA - English
Combined company will focus on advancing Chemomab s CM-101 currently in Phase 2 for rare fibrotic indications
Company to receive gross proceeds of $45.5 Million from a PIPE financing, led by healthcare-focused investors Cormorant Asset Management, OrbiMed, Peter Thiel and Christian Angermayer s Presight Capital and Apeiron Investment Group
News provided by
Share this article
Share this article
TEL-AVIV, Israel, March. 16, 2021 /PRNewswire/ Chemomab Ltd., a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced the completion of its merger with Anchiano Therapeutics Ltd. ( Anchiano ). ....

Christian Angermayer Presight , Irina Koffler , Nissim Darvish , Joel Maryles , Sharon Elkobi , Claude Nicaise , Neil Cohen , Peter Thiel , Goldfarb Seligman , Balan Moses , Stephen Squinto , Wadi Mor , Novo Nordisk , Prnewswire Chemomab Ltd , Apeiron Investment Group , Lifesci Advisors , Oppenheimer Co Inc , Kestrel Therapeutics Inc , Chemomab Therapeutics Ltd , Exchange Commission , Greenberg Traurig , Bristol Myers Squibb , Anchiano Therapeutics Ltd , Business Development , Chemomab Ltd , Anchiano Therapeutics ,

Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors
Passage BioFebruary 19, 2021 GMT
PHILADELPHIA, Feb. 19, 2021 (GLOBE NEWSWIRE) Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced the appointment of Maxine Gowen, Ph.D., to its board of directors, effective Feb. 18. Dr. Gowen is chief executive officer of Tamuro Bio, a post that she has held since July 2019.
“We are immensely excited to have Maxine join our board of directors,” said Dr. Bruce Goldsmith, president and chief executive officer of Passage Bio. “Her public company leadership and deep clinical development expertise will provide tremendous support to Passage Bio as we transition to a clinical development organization in the first half of 2021.” ....

University Of Pennsylvania , United States , Wharton School , Gwen Fisher , Bruce Goldsmith , Maxine Gowen , Tamuro Bio , Tadataka Yamada , Zofia Mita , Stephen Squinto , Sarah Mccabe , Stern Investor Relations Inc , Aclaris Therapeutics Inc , University Of Pennsylvania Gene Therapy Program , Trevena Inc , Idera Pharmaceuticals Inc , Research Development , Life Sciences Pennsylvania , Akebia Therapeutics Inc , Panorama Therapeutics Inc , University Of Bristol , Passage Bio Inc , University Of Sheffield , Exchange Commission , Wharton School Of The University Pennsylvania , Passage Bio ,

2021 MS Innovation Challenge Finalists Announced

2021 MS Innovation Challenge Finalists Announced
Bristol Myers Squibb and Lyfebulb announce 10 finalists chosen for the Lyfebulb-Bristol Myers Squibb “Addressing Unmet Needs in MS: An Innovation Challenge.”
During March 10-11, the following finalists will compete virtually for a grant of $25,000 to further develop their ideas and concepts that will address the unmet needs of people who are experiencing multiple sclerosis (MS). This award will also assist in raising an overall awareness about this chronic disease.
Angie Conley, Founder and CEO of Abilitech Medical
Jason DaSilva, Founder and President of AXS Lab
Luanne Dibernardo, Founder and CEO of Oro Sports
Peter Grande, Co-Founder of MUVE ....

Jason Dasilva , Darint Okuda , David Lyons , Lucy Jones , Kate Cronin , Teresa Wright Johnson , Bristol Myers Squibb , Tina Deignan , Stephen Squinto , Peter Grande , Luanne Dibernardo , Tish Scolnik , Pierluigi Mantovani , Angie Conley , David Hojah , Karin Hehenberger , Tim Coetzee , Neuroimmunology Imaging Program , Ut Southwestern Medical Center , National Multiple Sclerosis Society , Neuroinnovation Program , Ogilvy Health , Lyfebulb Bristol Myers Squibb , Unmet Needs , Product Developer , Patient Entrepreneur ,

Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement

Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement
Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement
Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need
Concurrent PIPE financing to be used to fund clinical trials for CM-101 in fibrotic indications, focusing on two rare diseases and backed by leading healthcare-focused investors OrbiMed and Peter Thiel
CAMBRIDGE, Mass. and TEL-AVIV, Israel, Dec. 15, 2020 Anchiano Therapeutics Ltd. (“Anchiano”) (Nasdaq: ANCN), a preclinical biopharmaceutical company, and Chemomab Ltd. (“Chemomab”), a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, announce their entry into a definitive merger agreement pursuant to which the shareholders ....

United Kingdom , Anchiano Adss , Ronen Bezalel , Stan Polovets , Neil Cohen , Peter Thiel , Shachar Hadar , Goldfarb Seligman , Stephen Squinto , Wadi Mor , Oppenheimer Co Inc , Chemomab Therapeutics Ltd , Exchange Commission , Company Annual Report On Form , Greenberg Traurig , Anchiano Therapeutics Ltd , Anchiano Therapeutics Ltd Contact , Business Development , Chemomab Ltd , Anchiano Therapeutics , Therapeutics Ltd , Transaction Current Chemomab , Current Report , Information About , Investor Relations , Solicitation Anchiano ,